everolimus

• 

Health-related quality of life with lenvatinib in combination with everolimus

By Sharon Deveson Kell|2022-07-28T14:27:48+00:0028 Jul 2022|Drug treatments|

Maintaining good health-related quality of life is important for all [...]

Read More

Comments Off on Health-related quality of life with lenvatinib in combination with everolimus

• 

Can adjuvant everolimus prevent recurrence following surgery?

By Sharon Deveson Kell|2022-06-08T07:53:18+00:008 Jun 2022|Drug treatments|

At the American Society of Clinical Oncology (ASCO) Annual Meeting [...]

Read More

Comments Off on Can adjuvant everolimus prevent recurrence following surgery?

• 

Telaglenastat plus everolimus in advanced kidney cancer

By Sharon Deveson Kell|2022-05-18T07:59:04+00:0018 May 2022|Drug treatments|

This phase 2 clinical trial (ENTRATA) looked at how safe [...]

Read More

Comments Off on Telaglenastat plus everolimus in advanced kidney cancer

• 

Telaglenastat plus cabozantinib or everolimus for advanced/metastatic kidney cancer

By Sharon Deveson Kell|2022-03-15T07:48:59+00:0015 Mar 2022|Drug treatments|

This phase 1 clinical trial looked at the safety, tolerability, [...]

Read More

Comments Off on Telaglenastat plus cabozantinib or everolimus for advanced/metastatic kidney cancer

• 

ASCO GU 2021: Combinations of lenvatinib plus pembrolizumab or everolimus improved survival in untreated patients with advanced kidney cancer

By Sharon Kell|2021-02-15T11:14:12+00:0015 Feb 2021|Drug treatments|

Results from the phase 3 CLEAR study, presented at the [...]

Read More

Comments Off on ASCO GU 2021: Combinations of lenvatinib plus pembrolizumab or everolimus improved survival in untreated patients with advanced kidney cancer

• 

Lenvatinib plus everolimus for non clear cell kidney cancer

By Sharon Kell|2020-11-20T15:54:19+00:0020 Nov 2020|Uncategorized|

Treating non-clear cell renal cell carcinoma (RCC) is challenging because [...]

Read More

Comments Off on Lenvatinib plus everolimus for non clear cell kidney cancer

• 

Everolimus and bevacizumab for advanced papillary kidney cancer

By Sharon Kell|2020-10-30T09:00:31+00:0030 Oct 2020|Uncategorized|

In this phase 2 clinical trial, a combination of everolimus [...]

Read More

Comments Off on Everolimus and bevacizumab for advanced papillary kidney cancer

• 

Phase 1 trial of vorolanib plus everolimus for advanced kidney cancer

By Sharon Kell|2020-05-11T08:55:40+00:0011 May 2020|Uncategorized|

A new combination of vorolanib, a tyrosine kinase inhibitor plus [...]

Read More

Comments Off on Phase 1 trial of vorolanib plus everolimus for advanced kidney cancer

• 

ASCO GU 2020: Randomised clinical trial of HIF-2α inhibitor in patients with advanced kidney cancer

By Sharon Kell|2020-02-21T14:08:36+00:0021 Feb 2020|Drug treatments|

A randomised clinical trial of hypoxia inducible factor 2α (HIF-2α) [...]

Read More

Comments Off on ASCO GU 2020: Randomised clinical trial of HIF-2α inhibitor in patients with advanced kidney cancer

• 

ASCO GU 2020: Five-year survival data for metastatic kidney cancer patients treated with nivolumab

By Sharon Kell|2020-02-21T13:50:11+00:0021 Feb 2020|Uncategorized|

Five-year follow-up results from the phase 3 CheckMate-025 study, which [...]

Read More

Comments Off on ASCO GU 2020: Five-year survival data for metastatic kidney cancer patients treated with nivolumab